12:00 AM
 | 
Nov 25, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Balugrastim regulatory update

Teva said it withdrew a BLA for balugrastim, a long-acting recombinant human G-CSF fused to human albumin that had been under FDA review for neutropenia....

Read the full 101 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >